|
|
2411 Stanwell Drive
Concord, CA 94520 USA
phone:(925) 288-6000
fax:(925) 288-6001
|
|
| Symbol |
CERS |
| Exchange |
NASDAQ GM |
| Founded |
1991 |
| Employees |
83 |
|
|
| www.cerus.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Controlling biological replication to treat cancer, infectious disease, and blood safety. |
|
| Management |
| Claes Glassell, President and CEO; William J. Dawson, CFO; Laurence M. Corash, M.D., VP and Chief Medical Officer; David N. Cook, Ph.D., VP of R&D; William M. Greenman, President Cerus Europe, Howard G. Ervin, Vice President, Legal Affairs; Lori L. Roll, Vice President, Administration and Corporate Secretary |
| |
|
|
|
|
|
|
|
| Keywords |
| blood purification, platelets, plasma, red blood cells, white blood cells, blood, hepatitis c, vaccine, cancer, infectious disease, blood safety
, InfectiousDisease |
|
|
|
| Description |
|
Cerus Corporation is developing medical systems and therapeutics based on its proprietary Helinx technology for controlling biological replication. The company products are focused on cancer, infectious disease and blood safety. |
|
| Products / Services |
Cerus develops cancer immunotherapies based on its Listeria vaccine platform combined with disease antigens.
The INTERCEPT Blood System enhances the safety of donated blood components by inactivating viruses, bacteria, other pathogens and white blood cells.
|
|
| Technology / Differentiation |
| The INTERCEPT Blood System targets and inactivates blood-borne pathogens, such as HIV and hepatitis B and C, as well as harmful white blood cells, while leaving the therapeutic properties of the blood components intact. |
|
| Market / Customers |
The market for blood products is over $10 billion and growing, and with more than 90 million units of blood donated world-wide every year.
|
|
| Competitors / Substitutes / Alternatives |
Cypress Bioscience Inc, Immucor Inc and Technologies, Inc.
|
|
| Strategy |
The company's most advanced programs are focused on systems to enhance the safety of blood products used for transfusion.
|
|
| Status |
| Cerus has three therapeutic cancer vaccine products in development using their Listeria vaccine platform; one in collaboration with MedImmune, Inc., and two with The Johns Hopkins University. They are also collaborating with BioOne Corporation on the INTERCEPT Blood System. This product is currently being marketed for platelets in Europe. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members